The University of Texas MD Anderson Cancer Center and Radiopharm Theranostics have launched a joint venture to develop and commercialize radiopharmaceutical therapeutics for cancer.
Radiopharm Ventures leverages MD Anderson’s innovative technologies in antigen discovery and molecular imaging with Radiopharm’s expertise in developing and marketing radiopharmaceutical products.
The joint venture will initially focus on developing four or more therapies based on MD Anderson intellectual property, including an antibody against the tumor specific antigen B7-H3, which is highly expressed in several common tumors.
“Based on our early preclinical data, B7-H3 represents a promising radiotherapeutic target, and we look forward to having the opportunity to work with the team at Radiopharm with the goal of advancing our therapeutic candidate toward future clinical studies,” says David Piwnica-Worms, chair of Cancer Systems Imaging at MD Anderson.
“Radiopharmaceuticals continue to be rapidly developed as a highly promising therapeutic frontier in oncology,” says Riccardo Canevari, CEO of Radiopharm. “We are pleased to have this opportunity to collaborate with MD Anderson and its tremendous scientists as we work to make significant in-roads into cancer therapy for the benefit of patients.”
Source: MD Anderson Center
